Aclaris Therapeutics, Inc. (ACRS) stock forecast and price target
Price $3.92 · data as of November 13, 2026
12-month price target
Average target$10.36
Upside / downside+164.4%
Analysts11
ConsensusStrong buy
Low $4.00Average $10.36High $16.00
Gold marker: average target · white marker: today’s price ($3.92)
Analyst ratings
Strong buy 1Buy 10Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.60 | −12.6% | $6M |
| Next fiscal year ends December 31, 2027 | $-0.70 | −17.6% | $5M |
| Next quarter ends December 31, 2026 | $-0.17 | −5.7% | $1M |
| Quarter after ends March 31, 2027 | $-0.20 | −33.3% | $1M |
Consensus of the analysts covering Aclaris Therapeutics, updated daily. In the last 30 days 6 estimates were raised and 0 lowered.
Frequently asked questions
What is the Aclaris Therapeutics stock price target?
The average 12-month target from 11 analysts is $10.36, 164.4% above the current price of $3.92 Targets range from $4.00 to $16.00.
Is Aclaris Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 10 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Aclaris Therapeutics expected to earn?
Analysts expect EPS of $-0.60 for the fiscal year ending December 31, 2026 and $-0.70 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.